Any current/future new fundraising through debt or equity?

There are currently **no plans to raise equity** through QIP or any other means. (Page 10) On the **debt front**, the company expects debt to peak around FY25 due to ongoing CAPEX projects. Net debt is currently about Rs. 5,250 crores, expected to increase by approximately Rs. 500 crores but likely not to exceed Rs. 5,500 crores after amortization. (Pages 11-12) Debt servicing is planned to be managed through cash generation from normal business operations, with no indication of new major fundraising beyond this. (Page 10) Any new investment plans requiring additional funds will be communicate

Any current/future capex/capital investment/strategic investment?

FY25 CAPEX planned at about $100 million, including: - PET chips resin plants (Egypt: $70 million; India: $20-25 million residual CAPEX) - Aseptic packaging debottlenecking - Other miscellaneous expansions Maintenance CAPEX of approximately Rs. 140-150 crores per year is separate and additional PET chips plant in India expected to be fully operational by end of the current fiscal; cost benefits expected from Q2 FY25 onwards PCR (Post-Consumer Recycled) line CAPEX in Egypt: about $13-15 million with a 3-year payback period No current plans to expand PCR facility in India beyond pilot scal

Future growth expectations in sales/revenue/volumes?

India market demand growth is healthy at 10%-12% annually; overall demand-supply mismatch expected to resolve in a couple of years (Page 14). Packaging films business in India is currently under pricing pressure due to oversupply; margins and volumes expected to improve with demand-supply equilibrium (Pages 14, 17). Exports from India increased by 13% this quarter, indicating growth momentum (Page 5). Nigeria volumes up 60% YoY with utilization at 70%; target utilization 75%-80% considering export opportunities to America and ECOWAS (Page 6). Mexico plant volume grew nearly 100% YoY, w

Future growth expectations in earnings/operating earnings/profits/EPS?

EBITDA margins are expected to improve from the current ~12.5% towards a normalized range of 14.5% to 15%, driven by better demand-supply equilibrium and improved European market sentiment. Margins may see positive impact due to local sourcing benefits amid global supply chain disruptions like the Red Sea crisis. The backlog CAPEX, including PET chips plants in India and Egypt (about Rs. 150 crores), will lead to better cost control from FY25, potentially improving margins from Q2 FY25 onward. Volume growth continues, e.g., packaging films up 6.5% YoY and packaging up 3.6% YoY; Nigerian plant

UflexQ3 FY24Industrial Products

Uflex Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹650P/E: 6.9Market Cap: ₹4.8K CrSector: Industrial Products

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Order

N/A

Capex

Yes

1 of 4 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

India market demand growth is healthy at 10%-12% annually; overall demand-supply mismatch expected to resolve in a couple of years (Page 14).
Packaging films business in India is currently under pricing pressure due to oversupply; margins and volumes expected to improve with demand-supply equilibrium (Pages 14, 17).
Exports from India increased by 13% this quarter, indicating growth momentum (Page 5).
Nigeria volumes up 60% YoY with utilization at 70%; target utilization 75%-80% considering export opportunities to America and ECOWAS (Page 6).
Mexico plant volume grew nearly 100% YoY, with America markets robust and capacity at 92%-100% utilization (Page 7, 9).
Completion of backward integration facilities for PET chips in India and Egypt expected to add price benefits and volume reliability, aiding growth (Pages 5, 6).
Aseptic packaging capacity expansion to 12 billion packs expected to contribute positively by FY25 (Page 5).
Overall, cautious optimism for sharper recovery in next few quarters amid global market uncertainties (Pages 4, 11).

Margin guidance

Category 2

EBITDA margins are expected to improve from the current ~12.5% towards a normalized range of 14.5% to 15%, driven by better demand-supply equilibrium and improved European market sentiment.
Margins may see positive impact due to local sourcing benefits amid global supply chain disruptions like the Red Sea crisis.
The backlog CAPEX, including PET chips plants in India and Egypt (about Rs. 150 crores), will lead to better cost control from FY25, potentially improving margins from Q2 FY25 onward.
Volume growth continues, e.g., packaging films up 6.5% YoY and packaging up 3.6% YoY; Nigerian plant utilization is expected to ramp from current ~70% to 75-80%.
Debt levels expected to peak in FY25 (~Rs. 5,500 crores) with no major equity raise planned, and cash flow from operations will service debt.
Recovery in spreads depends on market conditions; improvement expected with correction in oversupply and demand recovery globally over next 4-6 months.

See what Uflex management said on margin guidance — free account, 30 seconds.

Fundraise plans

There are currently no plans to raise equity through QIP or any other means. (Page 10)
On the debt front, the company expects debt to peak around FY25 due to ongoing CAPEX projects. Net debt is currently about Rs. 5,250 crores, expected to increase by approximately Rs. 500 crores but likely not to exceed Rs. 5,500 crores after amortization. (Pages 11-12)
Debt servicing is planned to be managed through cash generation from normal business operations, with no indication of new major fundraising beyond this. (Page 10)
Any new investment plans requiring additional funds will be communicated to the market as they arise. (Page 10)

Order book

The transcript does not explicitly mention current or expected orderbook/pending orders for UFlex Limited in the Q3 FY24 earnings call held on February 13, 2024. - There is no direct reference to orderbook size or pending orders in the provided sections. - The discussion primarily focuses on capacity utilization, margins, market demand-supply dynamics, expansions, and operational highlights. - India and overseas capacity utilization and volume growth were discussed but without mention of orderbook specifics. - Expansion plans and capacity utilization in regions like Nigeria, Mexico, and America were mentioned in the context of market demand. - The company expects growth with normalized utilization and improved demand-supply balance over the next 1-2 years, but no quantified orderbook details are shared. Hence, specific data on current or expected orderbook/pending orders was not disclosed in the referenced transcript.

See what Uflex management said on order book — free account, 30 seconds.

Capex plans

Yes

FY25 CAPEX planned at about $100 million, including:
- PET chips resin plants (Egypt: $70 million; India: $20-25 million residual CAPEX)
- Aseptic packaging debottlenecking
- Other miscellaneous expansions
Maintenance CAPEX of approximately Rs. 140-150 crores per year is separate and additional
PET chips plant in India expected to be fully operational by end of the current fiscal; cost benefits expected from Q2 FY25 onwards
PCR (Post-Consumer Recycled) line CAPEX in Egypt: about $13-15 million with a 3-year payback period
No current plans to expand PCR facility in India beyond pilot scale due to economic feasibility concerns
No plans to raise equity through QIP or asset sales currently
Debt levels expected to peak around Rs. 5,500 crores in FY25, with amortization ongoing

Track Uflex — get its next earnings analysis in your feed

How does Uflex rank vs peers in Industrial Products?

Pro feature

ThisUflex

Rev 3Mar 2

See where Uflex sits in Industrial ProductsSee which companies these are, and every other name in the sector.Open rankings

How does Uflex rank in Industrial Products?

Compare Uflex against every Industrial Products company (Q3 FY24) on revenue, margins and earnings-call signals.

View Industrial Products leaderboard →

What Uflex Ltd's management said in earlier quarters

Others in Industrial Products this season

Monolithisch India Ltd (Q2 FY27)
Combined additional capacity: 3 lakh MT per annum; total capex approximately INR 45 crores. Key concall takeaways from Monolithisch India Ltd's Q2 FY27…
Systematic Industries Ltd (Q1 FY27)
Year-on-Year (YoY) Growth for Q4 Net Sales:** 6.0% . Key concall takeaways from Systematic Industries Ltd's Q1 FY27 earnings call — and how it ranks against…
Graphite India Ltd (Q3 FY24)
690 crore, down 1.6% y-o-y (Page 5, 9) . Key concall takeaways from Graphite India Ltd's Q3 FY24 earnings call — and how it ranks against sector peers.
Graphite India Ltd (Q4 FY24)
720 Cr, down 11.7% y-o-y (Page 4, 9) . Key concall takeaways from Graphite India Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.

Compare:vs Polycab India Ltd vs Welspun Corp Ltd vs APL Apollo Tubes

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →